视网膜药物市场规模、份额、成长分析（依药物类别、适应症、剂型、通路、地区）－2025-2032 年产业预测

2023 年全球视网膜药物市场规模为 202 亿美元，预计将从 2024 年的 218.6 亿美元成长到 2032 年的 410.6 亿美元，预测期内（2025-2032 年）的复合年增长率为 8.2%。

由于老龄化黄斑部病变(AMD)、糖尿病视网膜病变和视网膜静脉阻塞 (RVO) 等视网膜疾病在全球范围内流行，影响着全球超过 1.96 亿人，视网膜药物市场正在经历显着增长。人口老化、糖尿病患者数量增加以及眼科诊断和治疗机会的改善等因素正在加速市场发展。市场主要由抗 VEGF 药物主导，例如阿柏西普 (Eylea)、雷珠单抗 (Lucentis) 和溴珠单抗 (Beovu)，仅 Eylea 的全球销售额就超过 90 亿美元。此外，创新的缓释性药物传递系统和基因疗法正在透过减少注射次数彻底改变治疗方法，这对于患者的依从性至关重要。 Regenxbio、Roche 和 Kodiak Sciences 等主要企业凭藉先进的长效疗法和玻璃体内植入引领这一领域。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 二次资料和一次资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分机会分析

市场动态与展望

• 市场概览
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

关键市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024年）
• PESTEL分析
• 总体经济指标
• 价值链分析
• 定价分析
• 价值链分析
• 监管机构
• 研发线产品分析
• 案例研究

视网膜药物市场规模（依药物类别及复合年增长率）（2025-2032 年）

• 市场概览
• 抗VEGF药物
  • VEGF-A拮抗剂
  • 双标靶抗血管新生药物
• 皮质类固醇
  • 玻璃体内植入
  • 注射悬浮液
• 免疫调节药物
• 基因和细胞治疗
• 小分子疗法
• 其他药物类别

视网膜药物市场规模（按适应症和复合年增长率） (2025-2032)

• 市场概览
• 黄斑部病变
• 糖尿病视网膜病变
• 葡萄膜炎
• 其他的

视网膜药物市场规模（按处方和复合年增长率） (2025-2032)

• 市场概览
• 注射剂（溶液、悬浮液）
• 植入（生物分解性、非生物分解）
• 眼药水
• 口服片剂和胶囊
• 软膏和凝胶

视网膜药物市场规模（依分销管道划分）及复合年增长率（2025-2032）

• 市场概览
• 医院药房
• 零售药局
• 网路药局

视网膜药物市场规模（按地区）及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市场占有率分析（2024年）
• 主要企业简介
  • 公司详情
  • 产品系列分析
  • 公司分部份额分析
  • 收益与前一年同期比较对比（2022-2024 年）

主要企业简介

• Roche Holding AG（incl. Genentech）
• Regeneron Pharmaceuticals, Inc.
• Novartis AG
• Bayer AG
• Allergan（AbbVie Inc.）
• Alcon Inc.
• Santen Pharmaceutical Co., Ltd.
• MeiraGTx Holdings plc
• Ocuphire Pharma, Inc.
• Kodiak Sciences Inc.
• Adverum Biotechnologies, Inc.
• Oxurion NV
• Graybug Vision, Inc.
• Clearside Biomedical, Inc.
• Outlook Therapeutics, Inc.
• Iveric Bio（acquired by Astellas Pharma）
• Sandoz（a Novartis spin-off for biosimilars）
• Coherus BioSciences, Inc.
• Biogen Inc.

结论和建议

Global Retinal Drugs Market size was valued at USD 20.20 Billion in 2023 and is poised to grow from USD 21.86 Billion in 2024 to USD 41.06 Billion by 2032, growing at a CAGR of 8.2% during the forecast period (2025-2032).

The retinal drugs market is witnessing significant growth driven by the global prevalence of retinal diseases like age-related macular degeneration (AMD), diabetic retinopathy, and retinal vein occlusion (RVO), affecting over 196 million people globally. Factors such as an aging population, rising diabetes cases, and enhanced access to ophthalmic diagnostics and treatments have amplified market development. Dominating the landscape are anti-VEGF drugs like aflibercept (Eylea), ranibizumab (Lucentis), and brolucizumab (Beovu), with Eylea alone generating over $9 billion in global sales. Additionally, innovative sustained-release drug delivery systems and gene therapy are revolutionizing treatment approaches by reducing injection frequency, which is critical for patient compliance. Key players like Regenxbio, Roche, and Kodiak Sciences are leading the charge with advanced longer-acting therapies and intravitreal implants.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Retinal Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Retinal Drugs Market Segments Analysis

The global Retinal Drugs market is segmented on the basis of Drug Classes, Indication, Formulation, Application, Distribution Channel and region. By Drug Classes, the market is segmented into Anti-VEGF Agents, Corticosteroids, Immunomodulators, Gene & Cell Therapies, Small Molecule Therapies, and Others. By Indication, the market is segmented into Macular Degeneration, Diabetic Retinopathy, Uveitis, and Others. Based on Formulation, the market is segmented into Injectables, Implants, Eye Drops, Oral Tablets/Capsules, and Ointments & Gels. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. By region, the market is segmented into North America, Europe, Asia Pacific, the Middle East and Africa, and Latin America.

Driver of the Global Retinal Drugs Market

The expansion of the global retinal drugs market can be attributed significantly to the rising prevalence of retinal diseases, including age-related macular degeneration (AMD), diabetic retinopathy (DR), and retinal vein occlusion (RVO). In 2020, it was reported that over 196 million individuals were affected by AMD, a number projected to reach 288 million by 2040. Additionally, nearly 188 million people suffer from diabetic retinopathy and around 16.4 million from RVO. Contributing factors such as aging populations, increased screen time, and poor dietary habits are further escalating retinal health issues, enhancing the demand for effective therapeutic interventions. As patients gain access to earlier diagnoses and treatments, there is an increasing need for innovative therapies, including anti-VEGF medications, corticosteroids, and gene therapies to address these growing health concerns.

Restraints in the Global Retinal Drugs Market

Despite advancements in retinal treatment, the exorbitant cost of retinal drugs poses a substantial hurdle to market growth, particularly in low- and middle-income nations. Anti-VEGF medications, which are regarded as a cornerstone for treating various retinal conditions, are often priced prohibitively high. For example, Lucentis can range from $1,200 to $2,000 per injection, and patients might require these injections monthly. While biosimilars like Byooviz are available at lower prices, they still remain unaffordable for many healthcare systems and patients. Long-term treatment regimens further exacerbate the financial strain, as many public healthcare systems in developing regions lack the necessary funding to support these medications, while private insurance plans often exclude coverage for retinal diseases or impose substantial copayments that deter patient compliance.

Market Trends of the Global Retinal Drugs Market

The Global Retinal Drugs market is witnessing a significant trend towards the adoption of gene therapy as a groundbreaking solution for inherited retinal diseases, particularly for conditions that lack existing therapies. Leading pharmaceutical companies are investing in advanced candidates such as Regenxbio's RGX-314 and Adverum's ADVM-022, which utilize AAV-based vectors to facilitate sustained anti-VEGF expression. Additionally, MeiraGTx is making strides in developing therapies targeting rare retinal dystrophies. Despite being in clinical or early regulatory phases, these innovative therapies hold substantial strategic value, attributed to orphan drug designations, the potential for one-time treatments, and considerable pricing leverage, thereby establishing gene therapy as a key player in the future of retinal care.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Value Chain Analysis
• Regulatory Bodies
• Pipeline Product Analysis
• Case Studies

Global Retinal Drugs Market Size by Drug Classes & CAGR (2025-2032)

• Market Overview
• Anti-VEGF Agents
  • VEGF-A Antagonists
  • Dual-target Anti-angiogenic Agents
• Corticosteroids
  • Intravitreal Implants
  • Injectable Suspensions
• Immunomodulators
• Gene & Cell Therapies
• Small Molecule Therapies
• Other Drug Classes

Global Retinal Drugs Market Size by Indication & CAGR (2025-2032)

• Market Overview
• Macular Degeneration
• Diabetic Retinopathy
• Uveitis
• Others

Global Retinal Drugs Market Size by Formulation & CAGR (2025-2032)

• Market Overview
• Injectables (Solutions, Suspensions)
• Implants (Biodegradable, Non-biodegradable)
• Eye Drops
• Oral Tablets/Capsules
• Ointments & Gels

Global Retinal Drugs Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Retinal Drugs Market Size & CAGR (2025-2032)

• North America (Drug Classes, Indication, Formulation, Distribution Channel)
  • US
  • Canada
• Europe (Drug Classes, Indication, Formulation, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Classes, Indication, Formulation, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Classes, Indication, Formulation, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Classes, Indication, Formulation, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Roche Holding AG (incl. Genentech)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Allergan (AbbVie Inc.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alcon Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Santen Pharmaceutical Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MeiraGTx Holdings plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ocuphire Pharma, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kodiak Sciences Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Adverum Biotechnologies, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Oxurion NV
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Graybug Vision, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Clearside Biomedical, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Outlook Therapeutics, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Iveric Bio (acquired by Astellas Pharma)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sandoz (a Novartis spin-off for biosimilars)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Coherus BioSciences, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations